About Seqens
Seqens is a Healthcare company based in Ecully (France) founded in 2003, and was acquired by SK Capital in December 2021. Contract manufacturing services for small molecules and peptides are provided. The company has 39 employees. Seqens has completed 2 acquisitions, including CELLforCURE and CU Chemie Uetikon. Its website seqens.com draws about 28 thousand monthly visits. Its Indian entity Monolom India Pharma Private Limited reported revenue of βΉ18.17 Cr. Seqens offers products and services including APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides.
Company details
Seqens was established in 2003 in Ecully, France, as a provider of contract manufacturing services within the pharmaceutical and chemical sectors. Operations focus on the production of small molecules and peptides for clients seeking outsourced manufacturing solutions. Services encompass development, scale-up, and commercial production, with facilities supporting global supply chains. The company operates primarily from European locations, emphasizing regulatory compliance and quality standards in its processes.
- Headquarters Ecully, France
- Employees 39
- Stage Acquired
- SectorsHealthcare
- Website seqens.com
- Social LinkedIn X YouTube
- Acquired by SK Capital (Dec 2021)
- Legal Name Monolom India Pharma Private Limited
- Date of Incorporation 27 Oct, 2017
- Jurisdiction Pune, Maharashtra, India
- Indian entity revenue₹18.17 Cr
FY 2025 · -1% YoY
- Indian entity net profit₹2.04 Cr
FY 2025 · 11% margin
- Indian entity EBITDA₹4.45 Cr
FY 2025 · 24% margin
- InvestorsEurazeo
& 4 more
- Employee Count39
- Investments & AcquisitionsCELLforCURE
& 1 more
- Acquired bySK Capital
(Dec 2021)
Associated legal entities of Seqens
Seqens operates through Monolom India Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Monolom India Pharma Private Limited CIN U24303PN2017FTC188118 | Active | 27 Oct 2017 | Pune, Maharashtra | ₹18.2 Cr | 39 | 4 | View details |
Products & Services of Seqens
Seqens offers a comprehensive portfolio of products and services, including APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients.
Manufacture generic and custom active pharmaceutical ingredients for industry use.
Wide range of ingredients for personal care market applications.
High-quality specialized chemical products for various applications.
Apps and channels of Seqens
its YouTube channel SEQENS has 346 subscribers and 30 videos.
Videos from Seqens
The most watched videos on Seqens's YouTube channel, SEQENS (346 subscribers). Click a video to play it here.
More on SEQENS.
Funding Insights of Seqens
- Total Rounds 3
- Investors Count 4
All 3 funding rounds of Seqens with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | Series A | β | Societe Generale Capital Partenaire | β | |
| Jun 2016 | Series A | β | Merieux Developement, Ardian | β | |
| Jun 2016 | Series A | β | β |
5 investors in total: 5 institutional.
Investors in Seqens
Seqens has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Eurazeo, Societe Generale Capital Partenaire and Merieux Developement.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are managed by Societe Generale Capital Partenaire. | capitalpartenaires.societegenerale.com | Paris, France | ||
Private equity and debt investments are managed across multiple sectors. | 1969 | eurazeo.com | Paris, France | |
| merieux-developpement.com | ||||
Private investment firm specializing in markets and partnerships. | ardian.com | |||
A global private investment firm focused on specialty sectors. | skcapitalpartners.com | New York, United States |
Investor details for Seqens
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Monolom India Pharma Private Limited (Seqens)
Monolom India Pharma Private Limited is the primary company behind Seqens. The board of Monolom India Pharma Private Limited currently have 4 directors; the longest-serving is Ben Zion Dolitzky, appointed in 2023. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ben Zion Dolitzky DIN 10048697 | Director | 24 Mar 2023 | 3 yrs 7 mo | Monolom India Pharma Private Limited |
| Adrien Aymery Joel Bresson DIN 10859851 | Director | 22 Jan 2025 | 1 yr 9 mo | Monolom India Pharma Private Limited |
| Ashutosh Vijay Joshi DIN 11161084 | Director | 30 Jun 2025 | 1 yr 4 mo | Monolom India Pharma Private Limited |
| Chiara . Bergerone DIN 10240183 | Director | Monolom India Pharma Private Limited |
People of Seqens
38 people are tracked at Seqens (16 in leadership, 22 in team); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Emily C. | IT Project Manager & Business Partner | Leadership |
Jean-Pierre Pilleux | Director Of Operations | Leadership |
Pierre Luzeau | CEO of SEQENS | Leadership |
Léonard Jacquemet | Project Director | Leadership |
Emmanuelle Morandi | Head Of Europe Sales - Generic Apis | Leadership |
Charlie S. | Managing Director | Leadership |
Vincent Milhau | Directeur Financier / Group CFO | Leadership |
Laurent Castor | Vice-president Specialty Ingredients | Leadership |
Alexandre Gultzgoff | Group Chief Information Officer | Leadership |
Paul Trouve | ISB R&d Business Partner & Head Of Infrastructure | Leadership |
Carole Fontaine | Operational Quality Director | Leadership |
Julien Boutet | Innovation & Biotechnology Director | Leadership |
Sophie Toussaint | Head Of Strategy | Leadership |
Guillaume Notheaux | R&d And Project Management BU Director | Leadership |
Victor Z. | Vice President And General Manager, Personal Care Business Unit | Leadership |
Cedric Ducros | Chief Procurement Officer | Leadership |
Alexandra Ngawa Zenang | Business Line Manager Pharma Advanced Specialties BU | Team |
Ronan Rocle | Sales & Business Development Manager CDMO Scandinavia, Eastern Europe & Israel | Team |
Allan Jensen | Commercial Manager | Team |
Lucile Balestra | Communication Manager Pharma And R&d | Team |
18 more people are available in the full profile.
Complete people profiles for Seqens
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Seqens
Figures of Monolom India Pharma Private Limited, the primary company behind Seqens, for FY 2025. Revenue was ₹18.17 Cr (-1% year on year). Net profit was ₹2.04 Cr (11% margin). EBITDA was ₹4.45 Cr (24% margin). Revenue has grown at a compounded annual rate of +5% over three years and +10% over five years.
- ₹18.17 CrRevenue · FY 2025 · -1% YoY
- ₹2.04 CrNet profit · 11% margin
- ₹4.45 CrEBITDA · 24% margin
- ₹3.44 CrPaid-up capital
- 39Employees (provident fund records)
- +5%Revenue CAGR, 3 years
- +10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Monolom India Pharma Private Limited are on its company page.
Detailed financial statements for Seqens
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Seqens
Seqens has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CELLforCURE and CU Chemie Uetikon.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops innovative technologies for cell and gene therapy products to advance medical treatments. | cellforcure.com | Paris, France | 2010 | Jul 2023 | β’β’β’β’ | |
Organic chemicals and pharmaceutical APIs are manufactured and distributed. | uetikon.com | Lahr, Germany | 1970 | May 2015 | β’β’β’β’ |
Complete acquisition details for Seqens
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Seqens
6 dated milestones of Seqens across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Seqens is founded.
- Acquisition Acquires CU Chemie Uetikon.
- Funding First funding round.
- Funding Latest funding round, Series A,.
- Exit Acquired by SK Capital.
- Acquisition Acquires CELLforCURE.
Web traffic of Seqens
The website of Seqens (seqens.com) receives about 28K visits a month.
- Monthly visits28K
▲ 15.2% vs previous month
Websites whose visitors overlap most with Seqens. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| specchemonline.com | 100% | #1,875,513 | View details | ||
| atamankimya.com | 100% | #564,531 | View details | ||
| vigon.com | 80% | 14.8K | #1,808,882 | View details | |
zehnder-systems.de | zehnder-systems.de | 73% | #1,360,553 | β | |
| lmt-tools.com | 69% | #1,709,770 | View details | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 10 similar websites and full traffic analytics for Seqens
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Seqens
Complete news archive for Seqens
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seqens
Seqens was founded in 2003 and raised its 1st funding round 13 years after it was founded.
Seqens is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.
Seqens has 39 employees.
The primary company behind Seqens, Monolom India Pharma Private Limited, reported revenue of βΉ18.17 Cr for FY 2025, down 1% year on year.
Seqens was established in 2003 in Ecully, France, as a provider of contract manufacturing services within the pharmaceutical and chemical sectors. Operations focus on the production of small molecules and peptides for clients seeking outsourced manufacturing solutions. Services encompass development, scale-up, and commercial production, with facilities supporting global supply chains. The company operates primarily from European locations, emphasizing regulatory compliance and quality standards in its processes.
Seqens offers APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients.
Seqens has made 2 acquisitions, including CELLforCURE, and CU Chemie Uetikon.
Seqens has 5 investors. Key investors include Eurazeo, Societe Generale Capital Partenaire, Merieux Developement, Ardian, and SK Capital.
Seqens operates through Monolom India Pharma Private Limited.
Yes. Seqens was acquired by SK Capital in December 2021.
The legal entities of Seqens currently have 4 directors, including Chiara . Bergerone, Ben Zion Dolitzky, Ashutosh Vijay Joshi and others.

